Immuno-Oncology for Esophageal Cancer
Open Access
- 11 August 2020
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 16 (32) , 2673-2681
Abstract
Esophageal cancer (EC) is the seventh most common cancer, with a poor prognosis for metastatic EC patients and limited effective drugs for treatment. Nivolumab and pembrolizumab, monoclonal antibod...Keywords
Funding Information
- ONO Pharmaceuticals and MSD
This publication has 44 references indexed in Scilit:
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2015
- Esophageal CarcinomaNew England Journal of Medicine, 2014
- Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trialThe Lancet Oncology, 2014
- Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control studyGut, 2013
- Preoperative Chemoradiotherapy for Esophageal or Junctional CancerNew England Journal of Medicine, 2012
- A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)Annals of Surgical Oncology, 2011
- A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapyCancer Chemotherapy and Pharmacology, 2010
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJournal of Clinical Oncology, 2010
- Phase II Study of Cisplatin and 5-Fluorouracil with Concurrent Radiotherapy in Advanced Squamous Cell Carcinoma of the Esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group Trial (JCOG9516)Japanese Journal of Clinical Oncology, 2004
- A phase II study of single-agent docetaxel in patients with metastatic esophageal cancerAnnals of Oncology, 2004